Eiger BioPharmaceuticals (EIGR) Highlights Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2019 Meetings

March 25, 2019 1:34 PM
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) today announced Phase 2 PREVENT study results in an oral presentation at ENDO 2019 in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles